tiprankstipranks
BeOne Medicines Ltd (MX:6160N)
:6160N
Mexico Market

BeOne Medicines Ltd (6160N) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

6160N Analyst Ratings

Strong Buy
16Ratings
Strong Buy
16 Buy
0 Hold
0 Sell
Based on 16 analysts giving stock ratings to
BeOne
Medicines Ltd
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

6160N Stock 12 Month Forecast

Average Price Target

Based on 16 Wall Street analysts offering 12 month price targets for BeOne Medicines Ltd in the last 3 months. The average price target is $574.34 with a high forecast of $657.96 and a low forecast of $499.04. The average price target represents a change from the last price of .
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
Highest Price Target$657.96Average Price Target$574.34Lowest Price Target$499.04
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nomura Analyst forecast on MX:6160N
Unknown Analyst
Nomura
Not Ranked
Nomura
$598.9
Buy
Reiterated
07/24/26
BeOne Medicines Ltd (6160) Gets a Buy from Nomura
UBS Analyst forecast on MX:6160N
Unknown Analyst
UBS
Not Ranked
UBS
$605.22
Buy
Reiterated
07/23/26
BeOne Medicines Ltd (6160) Receives a Buy from UBS
Macquarie Analyst forecast on MX:6160N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$568.5
Buy
Reiterated
07/13/26
BeOne Medicines Ltd (6160) Receives a Buy from Macquarie
HSBC Analyst forecast on MX:6160N
Unknown Analyst
HSBC
Not Ranked
HSBC
$499.04
Buy
Reiterated
07/10/26
HSBC Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
Huafu Securities Analyst forecast on MX:6160N
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
$657.96
Buy
Reiterated
07/06/26
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CICC Analyst forecast on MX:6160N
Unknown Analyst
CICC
Not Ranked
CICC
$553.02
Buy
Reiterated
06/03/26
BeOne Medicines Ltd (6160) Gets a Buy from CICC
Citi Analyst forecast on MX:6160N
Unknown Analyst
Citi
Not Ranked
Citi
$601.24
Buy
Reiterated
06/02/26
Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
Bank of America Securities Analyst forecast on MX:6160N
Bank of America Securities
Bank of America Securities
$539.3
Buy
Reiterated
05/21/26
BeOne Medicines Ltd (6160) Gets a Buy from Bank of America Securities
Citic Securities Analyst forecast on MX:6160N
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$530.9$517.62
Buy
Reiterated
05/12/26
Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CMBC International Analyst forecast on MX:6160N
Unknown Analyst
CMBC International
Not Ranked
CMBC International
$616.84
Buy
Reiterated
05/10/26
BeOne Medicines Ltd (6160) Gets a Buy from CMBC International
Bank of China Analyst forecast on MX:6160N
Unknown Analyst
Bank of China
Not Ranked
Bank of China
$530.9
Buy
Reiterated
05/07/26
Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
CLSA Analyst forecast on MX:6160N
Unknown Analyst
CLSA
Not Ranked
CLSA
$645.7
Buy
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Gets a Buy from CLSA
CMB International Securities Analyst forecast on MX:6160N
Unknown Analyst
CMB International Securities
Not Ranked
CMB International Securities
$520.85
Buy
Reiterated
05/07/26
CMB International Securities Remains a Buy on BeOne Medicines Ltd (6160)
UOB Kay Hian Analyst forecast on MX:6160N
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
$568.5
Buy
Reiterated
05/07/26
UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
DBS
$641.5
Buy
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Receives a Buy from DBS
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Nomura Analyst forecast on MX:6160N
Unknown Analyst
Nomura
Not Ranked
Nomura
$598.9
Buy
Reiterated
07/24/26
BeOne Medicines Ltd (6160) Gets a Buy from Nomura
UBS Analyst forecast on MX:6160N
Unknown Analyst
UBS
Not Ranked
UBS
$605.22
Buy
Reiterated
07/23/26
BeOne Medicines Ltd (6160) Receives a Buy from UBS
Macquarie Analyst forecast on MX:6160N
Unknown Analyst
Macquarie
Not Ranked
Macquarie
$568.5
Buy
Reiterated
07/13/26
BeOne Medicines Ltd (6160) Receives a Buy from Macquarie
HSBC Analyst forecast on MX:6160N
Unknown Analyst
HSBC
Not Ranked
HSBC
$499.04
Buy
Reiterated
07/10/26
HSBC Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
Huafu Securities Analyst forecast on MX:6160N
Unknown Analyst
Huafu Securities
Not Ranked
Huafu Securities
$657.96
Buy
Reiterated
07/06/26
Huafu Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CICC Analyst forecast on MX:6160N
Unknown Analyst
CICC
Not Ranked
CICC
$553.02
Buy
Reiterated
06/03/26
BeOne Medicines Ltd (6160) Gets a Buy from CICC
Citi Analyst forecast on MX:6160N
Unknown Analyst
Citi
Not Ranked
Citi
$601.24
Buy
Reiterated
06/02/26
Citi Keeps Their Buy Rating on BeOne Medicines Ltd (6160)
Bank of America Securities Analyst forecast on MX:6160N
Bank of America Securities
Bank of America Securities
$539.3
Buy
Reiterated
05/21/26
BeOne Medicines Ltd (6160) Gets a Buy from Bank of America Securities
Citic Securities Analyst forecast on MX:6160N
Unknown Analyst
Citic Securities
Not Ranked
Citic Securities
$530.9$517.62
Buy
Reiterated
05/12/26
Citic Securities Sticks to Its Buy Rating for BeOne Medicines Ltd (6160)
CMBC International Analyst forecast on MX:6160N
Unknown Analyst
CMBC International
Not Ranked
CMBC International
$616.84
Buy
Reiterated
05/10/26
BeOne Medicines Ltd (6160) Gets a Buy from CMBC International
Bank of China Analyst forecast on MX:6160N
Unknown Analyst
Bank of China
Not Ranked
Bank of China
$530.9
Buy
Reiterated
05/07/26
Bank of China Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
CLSA Analyst forecast on MX:6160N
Unknown Analyst
CLSA
Not Ranked
CLSA
$645.7
Buy
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Gets a Buy from CLSA
CMB International Securities Analyst forecast on MX:6160N
Unknown Analyst
CMB International Securities
Not Ranked
CMB International Securities
$520.85
Buy
Reiterated
05/07/26
CMB International Securities Remains a Buy on BeOne Medicines Ltd (6160)
UOB Kay Hian Analyst forecast on MX:6160N
Unknown Analyst
UOB Kay Hian
Not Ranked
UOB Kay Hian
$568.5
Buy
Reiterated
05/07/26
UOB Kay Hian Sticks to Their Buy Rating for BeOne Medicines Ltd (6160)
DBS
$641.5
Buy
Reiterated
05/07/26
BeOne Medicines Ltd (6160) Receives a Buy from DBS
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
MLYSMineralys Therapeutics, Inc.
AMLXAmylyx Pharmaceuticals Inc
ZURAZura Bio
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BeOne Medicines Ltd

3 Months
Success Rate
6/10 ratings generated profit
60%
Average Return
+1.26%
Copying Matthew Yan's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +1.26% per trade.
1 Year
Success Rate
8/10 ratings generated profit
80%
Average Return
+30.82%
Copying Matthew Yan's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +30.82% per trade.
2 Years
Success Rate
10/10 ratings generated profit
100%
Average Return
+50.15%
Copying Matthew Yan's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +50.15% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

6160N Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
1
4
7
9
5
Buy
5
12
9
13
4
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
6
16
16
22
9
In the current month, 6160N has received 9 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 6160N average Analyst price target in the past 3 months is 574.34.
Each month's total comprises the sum of three months' worth of ratings.

6160N Financial Forecast

6160N Earnings Forecast

Next quarter’s earnings estimate for 6160N is $2.21 with a range of $0.81 to $4.72. The previous quarter’s EPS was $2.61. 6160N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year 6160N has Performed in-line its overall industry.
Next quarter’s earnings estimate for 6160N is $2.21 with a range of $0.81 to $4.72. The previous quarter’s EPS was $2.61. 6160N beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 36.78% of the time in the same period. In the last calendar year 6160N has Performed in-line its overall industry.

6160N Sales Forecast

Next quarter’s sales forecast for 6160N is $28.22B with a range of $27.32B to $30.04B. The previous quarter’s sales results were $26.16B. 6160N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year 6160N has Performed in-line its overall industry.
Next quarter’s sales forecast for 6160N is $28.22B with a range of $27.32B to $30.04B. The previous quarter’s sales results were $26.16B. 6160N beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.91% of the time in the same period. In the last calendar year 6160N has Performed in-line its overall industry.

6160N Stock Forecast FAQ

What is MX:6160N’s average 12-month price target, according to analysts?
Based on analyst ratings, BeOne Medicines Ltd’s 12-month average price target is 574.34.
    What is MX:6160N’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for MX:6160N, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is BeOne Medicines Ltd a Buy, Sell or Hold?
        BeOne Medicines Ltd has a consensus rating of Strong Buy, which is based on 16 buy ratings, 0 hold ratings and 0 sell ratings.
          What is BeOne Medicines Ltd’s share price target?
          The average share price target for BeOne Medicines Ltd is 574.34. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $657.96 ,and the lowest forecast is $499.04. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about BeOne Medicines Ltd?
            BeOne Medicines Ltd’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
              How can I buy shares of BeOne Medicines Ltd?
              To buy shares of MX:6160N, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.